Kawai AT, Martinez D, Saltus CW, Vassilev ZP, Soriano-Gabarro M, Kaye JA. Incidence of skeletal-related events in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the US. Prostate Cancer. 2019 Jul 9. doi: 10.1155/2019/5971615
Saltus CW, Vassilev ZP, Zong J, Calingaert B, Andrews EB, Soriano-Gabarro M, Kaye JA. Incidence of second primary malignancies in patients with castration-resistant prostate cancer: an observational retrospective cohort study in the United States. Prostate Cancer. 2019 Feb 11;2019:4387415. doi: 10.1155/2019/4387415
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Camprodon-Rosanas E, Ribas-Fito N, Batlle-Vila S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Sluggish cognitive tempo: sociodemographic, behavioral, and clinical characteristics in a population of Catalan school children. J Atten Disord. 2017 Jun;21(8):632-41. doi: 10.1177/1087054716652477
Camprodon-Rosanas E, Ribas-Fito N, Batlle S, Persavento C, Alvarez-Pedrerol M, Sunyer J, Forns J. Association between sluggish cognitive tempo symptoms and attentional network and working memory in primary schoolchildren. J Atten Disord. 2017 Apr 1. doi: 10.1177/1087054717702245
Vilor-Tejedor N, Alemany S, Forns J, Caceres A, Murcia M, Macia D, Pujol J, Sunyer J, Gonzalez JR. Assessment of susceptibility risk factors for ADHD in imaging genetic studies. J Atten Disord. 2016 Aug 17.
Deal LS, Sleeper-Triplett J, DiBenedetti DB, Nelson L, McLeod L, Haydysch EE, Brown TM. Development and validation of the ADHD Benefits of Coaching Scale (ABCS). J Atten Disord. 2015 Mar;19(3):191-9. doi: 10.1177/1087054714558118
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.